Skip to main content

Table 4 Longitudinal analysis of sleep duration and insomnia with the risk of metabolic syndrome and its components using generalized estimating equation models

From: Association of sleep duration and insomnia with metabolic syndrome and its components in the Women’s Health Initiative

 

MetS

Waist > 88 cm

Hypertension

Model 1

Model 2

Model 1

Model 2

Model 1

Model 2

Average sleep hours

OR (95%CI)

OR (95%CI)

OR (95%CI)

OR (95%CI) a

OR (95%CI)

OR (95%CI) a

 < 6

1.11 (0.83–1.53)

0.98 (0.70–1.37)

1.06 (0.75–1.49)

1.04 (0.74–1.48)

1.41 (1.03–1.92)

1.35 (1.01–1.91)

 6- < 7

1.16 (0.90–1.49)

1.11 (0.86–1.42)

0.92 (0.70–1.20)

0.85 (0.65–1.11)

1.26 (0.99- 1.61)

1.24 (0.97–1.58)

 7- < 8

ref

ref

ref

ref

ref

ref

 8- < 9

1.14 (0.82–1.59)

1.13 (0.82–1.59)

0.62 (0.41–0.93)

0.62 (0.41–0.94)

1.05 (0.75–1.45)

1.02 (0.73–1.42)

 ≥ 9

0.62 (0.22–1.78)

0.68 (0.23–1.90)

0.40 (0.11–1.42)

0.43 (0.12–1.54)

1.00 (0.41–2.45)

1.09 (0.45–2.66)

 > 2 h increase

1.27 (0.74–2.18)

1.15 (0.67–2.00)

0.83 (0.40–1.70)

0.82 (0.40–1.69)

1.22 (0.68–2.19)

1.20 (0.66–2.17)

 > 2 h decrease

1.62 (1.00–2.62)

1.47 (0.90–2.37)

0.55 (0.25–1.20)

0.55 (0.25–1.21)

1.41 (0.83–2.38)

1.39 (0.82–2.37)

Quality of sleep over time

 Stable restful

ref

ref

ref

ref

ref

ref

 Restful to insomnia

1.44 (1.04–1.99)

1.40 (1.01–1.94)

1.04 (0.70–1.53)

1.07 (0.72–1.59)

1.26 (0.91–1.74)

1.27 (0.91–1.77)

 Insomnia to restful

1.16 (0.84–1.61)

1.14 (0.82–1.58)

1.34 (0.95–1.89)

1.28 (0.90–1.82)

0.81 (0.57–1.14)

0.80 (0.57–1.14)

 Persistent insomnia

1.39 (1.07–1.82)

1.31 (0.99–1.73)

1.18 (0.86–1.61)

1.05 (0.75–1.47)

1.12 (0.87–1.46)

1.10 (0.84–1.46)

 

Fasting glucose ≥ 100 mg/dL

Triglycerides ≥ 150 mg/dL

HDL < 50 mg/dL

Average sleep hours

OR (95%CI)

OR (95%CI) a

OR (95%CI)

OR (95%CI) a

OR (95%CI)

OR (95%CI) a

 < 6

1.47 (0.87–2.49)

1.19 (0.90–1.59)

0.85 (0.62–1.17)

0.79 (0.57–1.09)

1.17 (0.81–1.68)

1.06 (0.73–153)

 6- < 7

1.10 (0.77–1.57)

1.06 (0.85–1.32)

0.92 (0.73–1.16)

0.89 (0.70–1.13)

1.28 (0.97–169)

1.26 (0.96–1.66)

 7- < 8

ref

ref

ref

ref

ref

ref

 8- < 9

0.97 (0.64–1.44)

1.09 (0.81–1.47)

0.88 (0.63–1.22)

0.88 (0.63–1.22)

1.23 (0.85–1.77)

1.26 (0.87–1.82)

 ≥ 9

1.09 (0.42–2.85)

1.46 (0.71–3.03)

0.56 (0.21–1.51)

0.56 (0.21–1.51)

1.19 (0.46–3.04)

1.26 (0.49–3.24)

 > 2 h increase

1.13 (0.62–2.06)

0.94 (0.57–1.56)

1.37 (0.84–2.23)

1.32 (0.81–2.15)

0.90 (0.44–1.85)

0.92 (0.45–1.90)

 > 2 h decrease

0.92 (0.54–1.55)

0.96 (0.60–1.54)

0.98 (0.59–1.62)

0.98 (0.59–1.62)

1.37 (0.77–2.43)

1.26 (0.70–2.29)

Quality of sleep over time

 Stable restful

ref

ref

ref

ref

ref

ref

 Restful to insomnia

1.22 (0.92–1.61)

1.24 (0.93–1.65)

1.51 (1.10–2.06)

1.48 (1.08–2.03)

1.07 (0.73–1.57)

1.00 (0.68–1.47)

 Insomnia to restful

1.21 (0.92–1.58)

1.20 (0.91–1.58)

0.92 (0.67–1.26)

0.92 (0.67–1.27)

0.99 (0.68–1.43)

1.06 (0.72–1.54)

 Persistent insomnia

1.21 (0.95–1.53)

1.21 (0.94–1.56)

0.96 (0.73–1.26)

0.96 (0.73–1.26)

1.28 (0.95–1.72)

1.25 (0.91–1.71)

  1. Abbreviations: OR Odds ratio, CI Confidence interval, MetS metabolic syndrome, HDL high density lipoproteins 
  2. Model1 adjusted for age, ethnicity, and study participation
  3. Model 2 adjusted as model 1 plus clinical trial arm, educational level, hormone therapy use, smoking status, pack-years of smoking, alcohol intake, physical activity, coffee intake, depression, age at menopause, and marital status (see Table 2 for details)